Novartis to Buy Myricx Bio for $1.1 Billion to Add Novel ADC Payload Platform
Novartis has agreed to acquire UK-based Myricx Bio for $1.1 billion upfront plus up to $400 million in contingent milestones. The acquisition brings a potential first-in-class N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform — intended to address resistance to existing ADC payloads — and two lead ADC assets aim…